Alliance to Develop Cancer Assays

By HospiMedica staff writers
Posted on 29 Aug 2002

An alliance to develop cancer diagnostic assays has been announced by Fujirebio Diagnostics, Inc. (FDI, Malvern, PA, USA) and Randox, Ltd. (Crumlin, UK). The two companies will combine their proprietary technologies in the development of the assays.

Under the terms of the agreement, FDI has given Randox exclusive rights to develop and commercialize a tumor marker assay panel incorporating FDI's antibodies used in the CA125II, CA19-9, CA15-3, CA72-4 and Truquant tumor marker assays, for use on Randox's biochip array. The automated biochip technology allows the simultaneous determination of a panel of diagnostic markers from a single patient sample. The markers can be used in combination or as stand-alone tests. Recent studies have shown that multiplexing assay determinations using the same patient sample may improve diagnostic performance.

"The agreement with Randox is in line with our corporate strategy of being a content-driven diagnostics company and allows our standard-of-care markers to be formatted on a cutting-edge platform,” said Aris Petropoulos, president and chief operating officer, Fujirebio Diagnostics.

Related Links:
Fujirebio Diagnostics, Inc
Randox, Ltd